Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Year in Review
Year in Review
Year in Review
Safety Results of Phase 2 Study of Bintrafusp plus Chemotherapy in Advanced NSCLC (INTR@PID LUNG 024)
AACR & ASCO 2021 – Midyear Review
In patients with advanced squamous non–small-cell lung cancer (NSCLC), the combination of bintrafusp alfa and chemotherapy was well tolerated. The most common treatment-related adverse events were anemia, nausea, and pruritus.
Read More ›
Year in Review
Randomized Phase 3 Study of Sintilimab versus Docetaxel in Advanced Squamous NSCLC (ORIENT-3)
AACR & ASCO 2021 – Midyear Review
Compared with docetaxel, sintilimab significantly prolonged median overall survival by more than 3 months in patients with advanced squamous non–small-cell lung cancer (NSCLC).
Read More ›
Year in Review
Phase 1 Trial of VS-6766, a Dual RAF-MEK Inhibitor, and Defactinib, an FAK Inhibitor
AACR & ASCO 2021 – Midyear Review
In patients with non–small-cell lung cancer and
KRAS
G12V mutations who were pretreated with chemotherapy and immunotherapy, the combination of VS-6766 and defactinib is active with an acceptable tolerability profile.
Read More ›
Year in Review
Phase 2 Study of DM-CHOC-PEN in Patients with NSCLC with Central Nervous System Involvement
AACR & ASCO 2021 – Midyear Review
In patients with non–small-cell lung cancer (NSCLC) that involves the central nervous system and who lack genetic rearrangements or tumor targets, DM-CHOC-PEN, a bis-alkylator of DNA, has produced long-term objective responses with manageable toxicities.
Read More ›
Year in Review
Phase 2 Study of D-0316 in Patients with Advanced NSCLC and EGFR T790M Mutation
AACR & ASCO 2021 – Midyear Review
D-0316, a third-generation EGFR tyrosine kinase inhibitor (TKI), has antitumor activity and acceptable toxicity in patients with
EGFR
T790M–positive non–small-cell lung cancer (NSCLC) who progressed after EGFR-TKI treatment.
Read More ›
Year in Review
Phase 2 Study of Osimertinib + Oleclumab in Progressive T790M-Negative EGFR-Mutated NSCLC
AACR & ASCO 2021 – Midyear Review
The combination of a novel CD73 inhibitor, oleclumab, and osimertinib was well tolerated and effective in patients with advanced
EGFR
-mutated and T790M-negative non–small-cell lung cancer (NSCLC).
Read More ›
Year in Review
Phase 1 Study of Telisotuzumab Vedotin in Patients with c-Met–Mutated Advanced NSCLC
AACR & ASCO 2021 – Midyear Review
Telisotuzumab vedotin (teliso-V), an anti–c-Met antibody conjugated with a tubulin inhibitor payload, is active in selected patients with advanced c-Met–positive non–small-cell lung cancer (NSCLC).
Read More ›
Year in Review
Two-Year Update from CheckMate-9LA Study of Nivolumab plus Ipilimumab in Advanced NSCLC
AACR & ASCO 2021 – Midyear Review
With 2 years’ minimum follow-up, first-line use of nivolumab, ipilimumab, and chemotherapy offers durable survival relative to chemotherapy alone in patients with advanced non–small-cell lung cancer.
Read More ›
Year in Review
Rucaparib in High Genomic Loss of Heterozygosity and/or BRCA1/2-Mutated NSCLC (Lung-MAP Sub-Study, S1900A)
AACR & ASCO 2021 – Midyear Review
As a marker of homologous recombination deficiency, genomic loss of heterozygosity does not predict efficacy of rucaparib in advanced non–small-cell lung cancer (NSCLC).
Read More ›
Year in Review
Four-Year Update from CheckMate-227 Study of Nivolumab plus Ipilimumab in Advanced NSCLC
AACR & ASCO 2021 – Midyear Review
After 4 years’ follow-up, nivolumab combined with ipilimumab provides durable, long-term survival benefit compared with chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC) regardless of PD-L1 expression.
Read More ›
Page 8 of 9
1
2
3
4
5
6
7
8
9
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us